Are You or Anyone You Know on One
of These Drugs?
Biologic medicines, including many treatments for cancer, are the drugs of the future — but they’re extremely expensive. Herceptin, used for treating breast cancer, costs $48,000 a year and many insurance companies won’t even cover it.
Pharmaceutical companies are trying to use healthcare reform to make sure these drugs never become "generics" and stay extremely profitable. Young medical and public health students across the country feel their hands are being tied as healers of the future, and they are coming out in protest.
If you are someone you know are on any of these drugs and are having to foot the bill, or should be taking one but can’t afford to, please let us know.
| Brand Name | Drug | Indication | Pharmaceutical Company |
| Enbrel | etanercept | Rheumatoid arthritis and all other approved indications | Amgen & Wyeth & Takeda Pharmaceutical Co. |
| Remicade | infliximab | Rheumatoid arthritis et al. | Centocor (J&J) & Schering- Plough & Mitsubishi Tanabe Pharma |
| Epogen / Procrit /Eprex /ESPO | Epoetin alfa | Renal anemia and all other approved indications | Amgen & Ortho Biotech / Janssen- Cilag (J&J) & Kyowa Hakko Kirin Pharma |
| Rituxan /MabThera | rituximab | Non-Hodgkin’s lymphoma (NHL) and all other approved indications | Genentech; Biogen-IDEC, Roche |
| Humira Pen | adalimu-mab | Rheumatoid arthritis et al. | Abbott & Eisai |
| Avastin | bevacizu-mab | Metastatic colorectal cancer with 5-FU; 1st line NSCLC plus carboplatin & paclitaxel | Genentech & Roche & Chugai |
| Herceptin | trastuzu-mab | Her2 positive metastatic breast cancer et al. | Genentech; Chugai, Roche |
| Aranesp /NESP | darbepo-etin alfa | Anemia | Amgen & Kyowa Hakko Kirin Pharma |
| Neulasta | pegfilgra-stim | Neutropenia | Amgen |
| Lantus | insulin glargine | Type 1 and Type 2 diabetes | Sanofi-Aventis |
| Avonex | interferon beta-1a | Relapsing forms of multiple sclerosis | Biogen IdecI |
| Actrapid | rhu insulin Actrapid (EU)/Novolin (US) | Type 1 and 2 diabetes | Novo Nordisk |
| Lucentis | ranibizu-mab | Wet age-related macular degeneration (AMD) | Genentech & Novartis |
| Humalog Mix 50:50 premix | insulin lispro | Type 1 and 2 diabetes | Eli Lilly |
| Rebif | interferon beta-1a | Relapsing forms of multiple sclerosis | Merck Serono |
| NeoRecor-mo / Epogin/ Epoch | epoetin beta | Renal anemia and all other approved indications | Roche |
| Advate | Rec Anti-hemophilic Factor | Hemophilia A | Baxter Healthcare |
| Erbitux | cetuximab | Metastatic colo- rectal carcinoma and other labels | Eli Lilly (from ImClone acq.) & BMS & Merck Serono |
| Betaseron /Betaferon | interferon beta-1b | All relapsing forms of multiple sclerosis | Berlex & Bayer Schering Pharma |
| Pegasys | peginter-feron alfa-2a | Chronic hepatitis C virus infection + Copegus | Roche |
| Neupogen; | filgrastim | Neutropenia | Amgen |
| NovoLog (US) /NovoRapid (EU) | interferon aspart | Glycemic control in children and adults with diabetes mellitus | Novo Nordisk |
| Cerezyme | imiglucer-ase | Type 1 Gaucher disease | Genzyme |
| Synagis | palivizu-mab | Propylaxis of RSV infection | MedImmune |
| NovoSeven | eptacog alfa | Prevention and treatment of hemorrhage in hemophiliacs with alloantibodies | Novo Nordisk |
| Kogenate FS | Rec Anti-hemophilic Factor | Hemophilia A | Bayer Schering Pharma |
| Humulin 50:50; premix | human insulin | Type 1 and 2 diabetes | Eli Lilly |
